Molecular Therapy Nucleic Acids-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-09-23 west82b614f7

这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警

204 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-08-11 osmataku 来自北京

2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？

103 0

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-10-13 齐小丹

审稿速度:3.0
偏重的研究方向：RNA;神经
经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2021-11-24 ms4000001342707312

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：RNA结合蛋白;肿瘤
经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。

129 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-05-24 ms7000001796075615 来自广东省

审稿速度:2.0 | 投稿命中率:5.0
经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑

94 0

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2023-05-07 ms1000001579516810 来自山东省

偏重的研究方向：RNA;细胞生物学
经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢

83 0

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-01-17 ms9000001982912997

decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？

128 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-04-10 齐小丹

偏重的研究方向：分子治疗;神经
经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？

148 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-04-15 ms9000001939299214

中科院高度预警期刊，没必要讨论了

140 0

[GetPortalCommentsPageByObjectIdResponse(id=2089992, encodeId=9df020899928f, content=这个期刊子自引不到3%,每年发文不超500篇，就所谓国人占比也没超25%。中国人口占比全世界20%，那么到底根据什么给预警，若只是凭借国人占比，那么国产sci期刊一堆占比90%，怎么不，其他有些杂志社旗下一堆oncology reports之类期刊，怎么不预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6cf1717129, createdName=west82b614f7, createdTime=Fri Sep 23 18:35:58 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152217, encodeId=8439215221e11, content=2023年7月18日，浙江大学附属第一医院更新了“不建议投稿杂志名单”。医院根据中国科学院文献情报中心定期发布的《国际期刊预警名单》，设立《不建议投稿杂志名单》并动态更新。自2023年7月19日起，投稿以下杂志的论文，不得报销版面费。 28、Molecular Therapy-Nucleic Acids 这个杂志怎么情况了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Fri Aug 11 08:28:25 CST 2023, time=2023-08-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2093534, encodeId=9970209353455, content=审稿速度:3.0 偏重的研究方向：RNA;神经 经验分享：2021年11月31日投稿，2022年10月12日最终接收，历时11月余……审稿人很严谨负责，虽然改的大部分是小细节，虽然很痛苦……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Thu Oct 13 08:04:36 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138768, encodeId=7c722138e68f8, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：返修6个月，满足了大部分审稿人的意见，结果换了外国编辑被拒，巨黑，大家快跑快跑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af178477611, createdName=ms7000001796075615, createdTime=Wed May 24 10:02:46 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130657, encodeId=97c6213065ed0, content=偏重的研究方向：RNA;细胞生物学 经验分享：有没有最近投稿的？想了解下审稿流程和周期，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37c95472737, createdName=ms1000001579516810, createdTime=Sun May 07 03:25:59 CST 2023, time=2023-05-07, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1185120, encodeId=fbda1185120b4, content=decision in process 时间会变，你们遇到这种情况不？还有就是，decision in process后做决定一般多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Mon Jan 17 10:04:39 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209999, encodeId=d4e91209999a7, content=偏重的研究方向：分子治疗;神经 经验分享：二审1个半月后decision in process 2天了，是要拒稿了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=517c5541105, createdName=齐小丹, createdTime=Sun Apr 10 10:59:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211574, encodeId=a63a12115e49e, content=中科院高度预警期刊，没必要讨论了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d4f5694068, createdName=ms9000001939299214, createdTime=Fri Apr 15 23:41:17 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211049, encodeId=6b381211049ac, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：已经进了中科院预警，我就不介绍了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Thu Apr 14 08:08:39 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

2022-04-14 阳关月

审稿速度:6.0 | 投稿命中率:25.0
经验分享：已经进了中科院预警，我就不介绍了

171 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务